Colorectal Cancer Trial, Recruiting NCT04673955 Sponsor: Pierre Fabre Pharma GmbH Condition: Colorectal Cancer
Back to Colorectal Cancer

Colorectal Cancer Trial, Recruiting

NCT04673955
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older who are able to make their own legal decisions
  • People who have colorectal cancer that has spread to other parts of the body (metastatic), with a specific genetic change called the BRAF V600E mutation, and who have already received at least one previous cancer treatment
  • People whose doctor has already decided — independently of this study — to treat them with the combination of two drugs: encorafenib and cetuximab, based on their approved prescribing guidelines
  • People who either started that two-drug treatment within the last 3 months, or whose doctor is planning to start it soon
  • People who agree to have their data recorded for this study in an anonymised way and have signed a consent form

Who may not be able to join:

  • People who have already received more than 2 separate treatment courses for their metastatic cancer (some earlier treatments given before the cancer spread may also count toward this limit — confirm with trial site)
  • People who have previously been treated with a type of drug called a RAF-inhibitor or MEK-inhibitor
  • People for whom the two-drug combination (encorafenib and cetuximab) is medically unsuitable according to the official prescribing guidelines
  • People who are currently taking part in, or are about to take part in, another clinical trial that involves a treatment or procedure being tested
  • People who are currently receiving, or are about to receive, systemic treatment for a different type of cancer (other than this metastatic colorectal cancer)
  • People who are in prison or are being held in a facility involuntarily

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +4976115242627

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Pierre Fabre Pharma GmbH
Registry
ClinicalTrials.gov
Start date
3 September 2020
Est. completion
1 September 2026

Where this trial is recruiting

🇦🇹 Austria 🇩🇪 Germany

Primary endpoints

Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov